Kamada (NASDAQ:KMDA) Upgraded at StockNews.com

Kamada (NASDAQ:KMDA) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a report on Thursday, March 6th.

Kamada Stock Down 1.5 %

KMDA traded down $0.11 during trading on Thursday, reaching $7.23. The stock had a trading volume of 57,899 shares, compared to its average volume of 255,067. The stock has a 50 day moving average of $7.20 and a two-hundred day moving average of $6.20. The firm has a market capitalization of $415.58 million, a price-to-earnings ratio of 25.82, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97. Kamada has a 1-year low of $4.74 and a 1-year high of $9.15.

Institutional Investors Weigh In On Kamada

A number of institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new position in shares of Kamada in the 4th quarter valued at $67,000. Public Employees Retirement System of Ohio acquired a new position in shares of Kamada in the third quarter worth about $77,000. Plato Investment Management Ltd acquired a new position in shares of Kamada in the third quarter worth about $117,000. NewEdge Advisors LLC increased its position in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 8,260 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares during the period. 20.38% of the stock is owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.